BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28120720)

  • 1. The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives.
    Mahmood MQ; Shukla SD; Dua K; Shastri MD
    Curr Pharm Des; 2017; 23(16):2314-2320. PubMed ID: 28120720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
    Arnold D; Peinert S; Voigt W; Schmoll HJ
    Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies in gastrointestinal cancers.
    Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
    Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach.
    Ribeiro FA; Noguti J; Oshima CT; Ribeiro DA
    Anticancer Res; 2014 Apr; 34(4):1547-52. PubMed ID: 24692681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.
    Khan MH; Alam M; Yoo S
    Dermatol Surg; 2011 Sep; 37(9):1199-209. PubMed ID: 21615602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.
    Hofheinz RD; Segaert S; Safont MJ; Demonty G; Prenen H
    Crit Rev Oncol Hematol; 2017 Jun; 114():102-113. PubMed ID: 28477738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.
    Macarulla T; Casado E; Ramos FJ; Valverde C; Tabernero J
    Onkologie; 2006 Mar; 29(3):99-105. PubMed ID: 16514271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
    McIntire M; Redston M
    Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.
    Abdel-Rahman O
    Tumour Biol; 2015 Jan; 36(1):21-31. PubMed ID: 25394897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.
    Nautiyal J; Kanwar SS; Majumdar AP
    Curr Protein Pept Sci; 2010 Sep; 11(6):436-50. PubMed ID: 20491625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
    Li SN; Li HQ
    Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
    Huang S; Peter Rodemann H; Harari PM
    Recent Results Cancer Res; 2016; 198():45-87. PubMed ID: 27318681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
    Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A
    Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.